Filing Flows

Filing Flows › Companies › Prokidney › Cash flow

Prokidney cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$44.2M in Q2 2026 · −$160M over twelve months

Operating cash flow−$40.4M
Capital spending−$3.8M
Free cash flow−$44.2M

Analysis

In Q2 2026, Prokidney generated −$40.4M of operating cash flow and spent $3.8M on capital projects, leaving free cash flow of −$44.2M. That is $9.7M less than in Q2 2025 (−$34.5M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$141M; the largest uses were operating cash flow ($141M), capital spending ($18.6M), net borrowing (+) / repaid (−) ($8K); besides operations, cash came from other investing ($123M), shares issued ($26.4M); the cash balance fell by $10.1M.

Operating cash flow was −$40.4M against net income of −$46.4M. The largest differences: stock-based pay +$5.6M, payables −$2.7M, depreciation & amortization +$1.7M.

Free cash flow

Prokidney: free cash flow by quarterProkidney: free cash flow by quarter−$31.6MQ3 2024−$49.7MQ4 2024−$30.7MQ1 2025−$34.5MQ2 2025−$31.8MQ3 2025−$38.3MQ4 2025−$45.5MQ1 2026−$44.2MQ2 2026
Operating cash flow less capital spending.
Prokidney: operating cash flow against capital spendingProkidney: operating cash flow against capital spendingOperating cash flowCapital spending−$29.2M$2.4MQ3 2024−$24.2M$25.5MQ4 2024−$29.6M$1.1MQ1 2025−$31.4M$3.1MQ2 2025−$26.6M$5.2MQ3 2025−$32.5M$5.8MQ4 2025−$41.7M$3.8MQ1 2026−$40.4M$3.8MQ2 2026
Latest (Q2 2026): Operating cash flow −$40.4M, Capital spending $3.8M.

Capital allocation, year by year

Prokidney: where the cash came from (up) and went (down), by fiscal yearProkidney: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedAsset salesCapital spendingBuybacksFY2021: Operating cash flow −$50.3MFY2021: Net borrowing −$30KFY2021: Capital spending −$5.2MFY2021FY2022: Operating cash flow −$77.1MFY2022: Net borrowing −$32KFY2022: Asset sales $543MFY2022: Capital spending −$1.8M$543MFY2022FY2023: Operating cash flow −$90.1MFY2023: Net borrowing −$52KFY2023: Capital spending −$34.2MFY2023: Buybacks −$9.5MFY2023FY2024: Operating cash flow −$126MFY2024: Net borrowing −$54KFY2024: Shares issued $144MFY2024: Capital spending −$29.5M$144MFY2024FY2025: Operating cash flow −$120MFY2025: Net borrowing −$26KFY2025: Shares issued $25.6MFY2025: Capital spending −$15.2M$25.6MFY2025
Over these 5 years operating cash flow totalled −$464M; the largest uses were operating cash flow ($464M) and capital spending ($85.9M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$74.9M
Debtnone
Net cash$74.9M
Cash runway6 months

Prokidney is burning cash: its operations consume cash, a free cash flow of −$160M a year at the current rate against $74.9M of cash and investments: a runway of about 6 months before any new financing.

Where the cash came from and went

Prokidney: sources (+) and uses (−) of cash, Q2 2026Prokidney: sources (+) and uses (−) of cash, Q2 2026Operating cash flow−$40.4MCash drawn (+) / kept (−)$27.0MOther investing$16.6MCapital spending−$3.8MShares issued$546KNet borrowing (+) / repaid (−)−$5K
Prokidney: sources (+) and uses (−) of cash, TTM to Q2 2026Prokidney: sources (+) and uses (−) of cash, TTM to Q2 2026Operating cash flow−$141MOther investing$123MShares issued$26.4MCapital spending−$18.6MCash drawn (+) / kept (−)$10.1MNet borrowing (+) / repaid (−)−$8K

From profit to cash

Prokidney: net income to operating cash flow, Q2 2026Prokidney: net income to operating cash flow, Q2 2026Net income−$46.4MDepreciation & amortization$1.7MStock-based pay$5.6MGains on investments−$256KPayables−$2.7MPrepaid and other assets$1.7MOperating cash flow−$40.4M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$40.4M−$3.8M−$5K$546K$27.0M−$44.2M
Q1 2026−$41.7M−$3.8M−$3K$218K$6.6M−$45.5M
Q4 2025−$32.5M−$5.8M−$5K$17.6M−$13.2M−$38.3M
Q3 2025−$26.6M−$5.2M$5K$8.0M−$10.4M−$31.8M
Q2 2025−$31.4M−$3.1M−$14K—$12.9M−$34.5M
Q1 2025−$29.6M−$1.1M−$12K—$1.3M−$30.7M
Q4 2024−$24.2M−$25.5M−$14K$137K$9.0M−$49.7M
Q3 2024−$29.2M−$2.4M−$14K$4.5M$106M−$31.6M

Prokidney: income statement and cash flow

Prokidney, Q2 2026: revenue $150K (-32% year over year). The chart follows the revenue to costs, profit and cash.

Prokidney: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.